Last Update: 31-Dec-12 10:55 ET
The Healthcare sector (0.0%) is unchanged, underperforming the S&P 500
Gainers on news: STEM (+3.3%) StemCells filed amendment to sales agreement that raises the dollar amount of shares available to sell under the 2009 Sales Agreement back to $30 mln, PPHM (+2.4%) Peregrine Pharma filed for $75 mln secondary offering, BMY (+1.5%) Bristol-Myers and Pfizer (PFE) announced that FDA has approved ELIQUIS, COV (+0.8%) Covidien raised its FY13 net sales guidance for the Pharmaceuticals segment to 3-6% above 2012 from the previous range of 1-4%; Mallinckrodt launched generic version of CONCERTA in U.S., CLDX (+0.3%) Celldex Therapeutics: Ridgeback Capital Investments disclosed 6.1% position in 13G filing (denotes passive stake) out Friday after the close, JNJ (+0.1%) Johnson & Johnson: FDA granted accelerated approval for SIRTURO (bedaquiline) as part of combination therapy to treat adults with pulmonary multi-drug resistant tuberculosis, ELGX (+0.1%) Endologix IntuiTrak delivery system received Shonin approval for marketing in Japan; co also commented on alleged patent infringement... 'We believe we have strong defenses and that this potential dispute will not affect our commercial operations. We intend to aggressively defend our position'. Decliners on news: CRMD (-18.1%) Cormedix filed for $30 mln mixed securities shelf offering, DARA (-1.0%) DARA BioSciences to raise $2.8 mln pursuant to securities purchase agreement; funds earmarked for Soltamox commercial activities, Gelclair launch and working capital, DGX (-0.7%) Quest Diagnostics sold OralDNA Labs to Access Genetics; financial terms not disclosed, OPXA (-0.3%) Opexa Therapeutics filed for a ~1.703 mln share common stock shelf offering by by Lincoln Park Capital Fund, SRZ (-0.2%) Sunrise Senior Living announced special cash dividend of $2.10/share in connection with proposed merger with Health Care REIT (HCN). Broker calls: BMY (+1.5%) Bristol-Myers upgraded at Atlantic Equities, TSON (+1.2%) Trans1 initiated with an Outperform at Barrington Research, GALE (+1.0%) Galena Biopharma initiated with an Overweight at Piper Jaffray.
Gainers on news: STEM (+3.3%) StemCells filed amendment to sales agreement that raises the dollar amount of shares available to sell under the 2009